Sylvie Rusakiewicz
Lausanne, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer.
Journal: Frontiers in immunology
Published: December 08, 2025
Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2025
Genomic and Immune Landscape of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on Anti-PD-1 Treatment.
Journal: Cancer immunology research
Published: August 07, 2025
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan.
Journal: Cell reports methods
Published: May 27, 2025
IntegrAlign: a comprehensive tool for multi-immunofluorescence panel integration through image alignment.
Journal: Bioinformatics (Oxford, England)
Published: March 31, 2025
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 23, 2023
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 06, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Journal: Journal for immunotherapy of cancer
Published: September 03, 2023
Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids.
Journal: NPJ precision oncology
Published: June 28, 2023
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Journal: Nature communications
Published: June 21, 2022
Last Updated: 09/26/2026